nach oben

Die Radiologie

Erschienen in:

01.12.2007 | Leitthema: Interventionelle Onkologie

Update Chemoperfusion und -embolisation

verfasst von: A. Lubienski, M. Simon, K. Lubienski, J. Gellissen, R.-T. Hoffmann, T.F. Jakobs, T. Helmberger

Erschienen in: Die Radiologie | Ausgabe 12/2007

Einloggen, um Zugang zu erhalten

Zusammenfassung

Bildgesteuerte katheterinterventionelle und perkutan-ablative regionale Therapieverfahren haben in den letzten 2 Jahrzehnten in nichtresektablen Situationen die Therapie primärer und sekundärer Lebertumoren revolutioniert. Basierend auf dem zugrunde liegenden Prinzip werden chemoablative Verfahren von thermo- und radioablativen Verfahren unterschieden. Zu den chemoablativen interventionellen Verfahren gehören in erster Linie die transarterielle Chemoperfusion („HAIC, hepatic arterial infusion chemotherapy“) und die transarterielle (Chemo-)Embolisation (TACE/TAE). Ziel der transarteriellen Therapieverfahren ist es, eine maximale Konzentration eines Chemotherapeutikums oder einer Kombination von Chemotherapeutika direkt über die versorgenden Tumorgefäße in den Tumor zu geben und gleichzeitig die systemischen Wirkungen der Medikamente zu minimieren. Das Einsatzgebiet der transarteriellen Chemoperfusion an der Leber umfasst alle primären und sekundären Lebertumoren, hauptsächlich jedoch das hepatozelluläre Karzinom (HCC) und Metastasen kolorektalen Ursprungs.

Jemal A, Murray T, Ward E et al. (2005) Cancer statistics. CA Cancer J Clin 55: 10–30PubMedCrossRef

Choti MA, Bulkley GB (1999) Management of hepatic metastases. Liver Transpl Surg 5: 65–80PubMedCrossRef

Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet 362: 1907–1917PubMedCrossRef

Jonker DJ, Maroun JA, Kocha W (2000) Survival benefit of chemotherapy in metastatic colorectal cancer: a meta-analysis of randomized controlled trials. Br J Cancer 82: 1789–1794PubMedCrossRef

Lubienski A, Eckey T, Lubienski K et al. (2007) Interventionelle Verfahren zur Therapie von Lebertumoren. Viszeralchirurgie 42: 249–258CrossRef

Yamagami T, Kato T, Iida S et al. (2004) Value of transcatheter arterial embolization with coils and n-butyl cyanoacrylate for long-term hepatic arterial infusion chemotherapy. Radiology 230: 792–802PubMedCrossRef

Lai Y-C, Shih C-Y, Jeng C-M et al. (2003) Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with tumor thrombosis of the portal vein. World J Gastroenterol 9: 2666–2670PubMed

Tajima T, Yoshimitsu K, Kuroiwa T et al. (2005) Percutaneous femoral catheter placement for long-term chemotherapy infusion: preliminary technical results. Am J Roentgenol 184: 906–914

Yamagami T, Kato T, Tanaka O et al. (2005) Radiofrequency ablation therapy of remnant colorectal liver metastases after a course of hepatic arterial infusion chemotherapy. J Vasc Interv Radiol 16: 549–554PubMed

10.

Yamagami T, Iida S, Kato T et al. (2002) Using n-butyl cyanoacrylate and the fixed-catheter-tip technique in percutaneous implantation of a port-catheter system in patients undergoing repeated hepatic arterial chemotherapy. Am J Roentgenol 179: 1611–1617

11.

Morise Z, Sugioka A, Kato R et al. (2006) Transarterial chemoembolization with degradable starch microspheres, irinotecan, and mitomycin-C in patients with liver metastases. J Gastrointest Surg 10: 249–258PubMedCrossRef

12.

Sumie S, Yamashita F, Ando E et al. (2003) Interventional radiology for advanced hepatocellular carcinoma: comparison of hepatic artery infusion chemotherapy and transcatheter arterial lipiodol chemoembolization. Am J Roentgenol 181: 1327–1334

13.

Kemeny N, Garay CA, Gurtler J et al. (2004) Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. J Clin Oncol 22: 4753–4761PubMedCrossRef

14.

Folprecht G, Lutz MP, Schöffski P et al. (2006) Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 17: 450–456PubMedCrossRef

15.

Sangro B, Rios R, Bilbao I et al. (2002) Efficacy and toxicity of intra-arterial cisplatin and etoposide for advanced hepatocellular carcinoma. Oncology 62: 293–298PubMedCrossRef

16.

Arai Y, Inaba Y, Takeuchi Y, Ariyoshi Y (1997) Intermittent hepatic arterial infusion of high-dose 5FU on a weekly schedule for liver metastases from colorectal cancer. Cancer Chemother Pharmacol 40: 526–530PubMedCrossRef

17.

Meta-Analysis Group in Cancer (1996) Reappraisal of HAI in the treatment of nonresectable liver metastases from colorectal carcinoma. J Natl Cancer Inst 88: 252–258CrossRef

18.

Del Freo A, Fiorentini G, Sanguinetti F et al. (2006) Hepatic arterial chemotherapy with oxaliplatin, folinic acid and 5-flourouracil in pre-treated patients with liver metastases from colorectal cancer. In Vivo 20: 743–746

19.

Kemeny NE, Niedzwiecki D, Hollis DR et al. (2006) Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 24: 1395–1403PubMedCrossRef

20.

Kemeny N, Jarnagin W, Paty P et al. (2004) Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectalcancer. J Clin Oncol 23: 4888–4896CrossRef

21.

Ducreux M, Ychou M, Laplanche A et al. (2005) Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases:a trial of the Gastrointestinal Group of the Fédération Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 23: 4881–4887PubMedCrossRef

22.

Pohlen U, Rieger H, Mansmann U et al. (2006) Hepatic arterial infusion (HAI). Comparison of 5-fluorouracil, folinic acid, interferon alpha-2b and degradable starch microspheres versus 5-fluorouracil and folinic acid in patienst with non-resectable colorectal liver metastases. Anticancer Res 26: 3957–3964PubMed

23.

Van Hazel G, Blackwell A, Anderson J et al. (2004) Randomised phase 2 trial of SIR-spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 88: 78–85CrossRef

24.

Zhu AX, Fuchs CS, Clark JW et al. (2006) A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma. Oncologist 11: 87–88CrossRef

25.

Boige V, Taieb J, Hebbar M et al. (2006) Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin level. Eur J Cancer 42: 456–459PubMedCrossRef

26.

Hamada A, Yamakado K, Nakatsuka A et al. (2004) Hepatic arterial infusion chemotherapy with use of an implanted port system in patients with advanced hepatocellular carcinoma: prognostic factors. J Vasc Interv Radiol 15: 835–841PubMed

27.

Lerose R, Molinari R, Rocchi E et al. (2001) Prognostic features and survival of hepatocellular carcinoma in Italy: impact of stage of disease. Eur J Cancer 37: 239–245PubMedCrossRef

28.

Giannelli G, Pierri F, Trerotoli P et al. (2002) Occurrence of portal vein tumor thrombus in hepatocellular carcinoma affects prognosis and survival: a retropsective clinical study of 150 cases. Hepatol Res 24: 50PubMedCrossRef

29.

Iwamiya T, Sawada S, Ohta Y (1994) Repeated arterial infusion chemotherapy for inoperable hepatocellular carcinoma using an implantable drug delivery system. Cancer Chemother Pharmacol 33 [suppl]: S134–138

30.

Yamashita Y, Takahashi M, Koga Y et al. (1991) Prognostic factors in the treatment of hepatocellular carcinoma with transcatheter arterial embolization and arterial infusion. Cancer 67: 385–391PubMedCrossRef

31.

Gornet JM, Azoulay D, Duclos-Vallee JC, Goldwasser F et al. (2000) Complete remission of unresectable hepatocellular carcinoma on healthy liver by the combination of aggressive surgery and high-dose-intensity chemotherapy by CPT-11. Anticancer Drugs 11: 649–652PubMedCrossRef

32.

Lim TY, Cheong JY, Cho SW et al. (2006) Effect of low dose 5-fluorouracil and cisplatin intra-arterial infusion chemotherapy in advanced hepatocellular carcinoma with decompensated cirrhosis. Korean J Hepatol 12: 65–73PubMed

33.

Allen PJ, Nissan A, Picon AI et al. (2005) Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases. J Am Coll Surg 201: 57–65PubMedCrossRef

34.

Ricke J, Hildebrandt B, Miersch A et al. (2004) Hepatic arterial port systems for treatment of liver metastases: factors affecting patency and adverse events. J Vasc Interv Radiol 15: 825–833PubMed

35.

Venturini M, Angeli E, Salvioni M et al. (2004) Complications after percutaneous transaxillary implantation of a catheter for intraarterial chemotherapy of liver tumors: clinical management in 204 patients. Am J Roentgenol 182: 1417–1426

36.

Marelli L, Stigliano R, Triantos C et al. (2007) Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30: 6–25PubMedCrossRef

37.

Chung JW, Park JH, Im JG et al. (1993) Pulmonary oil embolism after transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 187: 689–693PubMed

38.

Kobayashi S, Narimatsu Y, Ogawa K et al. (1992) Transcatheter hepatic arterial chemoembolization using epirubicin-lipiodol: experimental and pharmacological evaluation. Cancer Chemother Pharmacol 31 [suppl]: S45–50

39.

Johnson PJ, Kalayci C, Dobbs N et al. (1991) Pharmacokinetics and toxicity of intraarterial adriamycin for hepatocellular carcinoma: effect of coadministration of lipiodol. J Hepatol 13: 120–127PubMedCrossRef

40.

Favoulet P, Cercueil JP, Faure P et al. (2001) Increased cytotoxicity and stability of lipiodol-pirarubicin emulsion compared to classical doxorubicin-lipiodol: potential advantage for chemoembolization of unresectable hepatocellular carcinoma. Anticancer Drugs 12: 801–806PubMedCrossRef

41.

Llado L, Virgili J, Figueras J et al. (2000) A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. Cancer 88: 50–57PubMedCrossRef

42.

Brown DB, Pilgram TK, Darcy MD et al. (2005) Hepatic arterial chemoembolization for hepatocellular carcinoma: comparison of survival rates with different embolic agents. J Vasc Interv Radiol 16: 1661–1666PubMed

43.

Seki H, Kimura M, Yoshimura N et al. (1998) Development of extrahepatic arterial blood supply to the liver during hepatic arterial infusion chemotherapy. Eur Radiol 8: 1613–1618PubMedCrossRef

44.

Lewis AL, Gonzalez MV, Lloyd AW et al. (2006) DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol 17: 335–342PubMedCrossRef

45.

Varela M, Real MI, Burrel M et al. (2007) Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 46: 474–481PubMedCrossRef

46.

Hong K, Khwaja A, Liapi E et al. (2006) New intra-arterial drug delivery system fort the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res 12: 2563–2567PubMedCrossRef

47.

Lewis AL, Gonzalez MV, Lloyd AW et al. (2006) Pharmacokinetic and safety study of doxorubicin-eluting beads in a porcine model of hepatic arterial embolization. J Vasc Interv Radiol 17: 1335–1343PubMed

48.

Huppert PE, Lauchart W, Duda SH et al. (2004) Chemoembolization of hepatocellular carcinomas: which factors determine therapeutic response and survival? Fortschr Röntgenstr 176: 375–385CrossRef

49.

Ho AS, Picus J, Darcy MD et al. (2007) Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. Am J Roentgenol 188: 1201–1207CrossRef

50.

Horiguchi Y, Itoh M, Takagawa H et al. (1992) Assessment of chemoembolization therapy for primary liver cancer using a stabilized adriamycin-lipiodol suspension. Cancer Chemother Pharmacol 31 [suppl]: S60–64

51.

Groupe d‘Etude et de Traitement du Carcinome Hepatocellulaire (1995) A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 332: 1256–1261CrossRef

52.

Bruix J, Llovet JM, Castells A et al. (1998) Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 27: 1578–1583PubMedCrossRef

53.

Lo CM, Ngan H, Tso WK et al. (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35: 1164–1171PubMedCrossRef

54.

Llovet JM, Real MI, Montana X et al. (2002) Barcelona liver cancer group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoima: a randomized controlled trial. Lancet 359: 1734–1739PubMedCrossRef

55.

Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 37: 429–442PubMedCrossRef

56.

Takayasu K, Arii S, Ikai I et al. (2006) Liver Cancer Study Group of Japan. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 131: 461–469PubMedCrossRef

57.

Wong LL, Tanaka K, Lau L, Komura S (2004) Pre-transplant treatment of hepatocellular carcinoma: assessment of tumor necrosis in explanted livers. Clin Transplant 18: 227–234PubMedCrossRef

58.

Graziadei IW, Sandmueller H, Waldenberger P et al. (2003) Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 9: 557–563PubMedCrossRef

59.

Kamel IR, Bluemke DA, Ramsey D et al. (2003) Role of diffusion-weighted imaging in estimating tumor necrosis after chemoembolization of hepatocellular carcinoma. Am J Roentgenol 181: 708–710

60.

Otto G, Herber S, Heise M et al. (2006) Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 12: 1260–1267PubMedCrossRef

61.

Mazzaferro V, Regalia E, Doci R et al. (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334: 693–699PubMedCrossRef

62.

Gupta S, Johnson MM, Murthy R et al. (2005) Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 104: 1590–1602PubMedCrossRef

63.

Ruutiainen AT, Soulen MC, Tuite CM et al. (2007) Chemoembolization and bland embolization of neuroendocrine tumor metastases to the liver. J Vasc Interv Radiol 18: 847–855PubMedCrossRef

64.

Patel K, Sullivan K, Berd D et al. (2005) Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study. Melanoma Res 15: 297–304PubMedCrossRef

65.

Li XP, Meng ZQ, Guo WJ, Li J (2005) Treatment for liver metastases from breast cancer: results and prognostic factors. World J Gastroenterol 11: 3782–3787PubMed

66.

Herber S, Otto G, Schneider J et al. (2007) Transarterial chemoembolization (TACE) for inoperable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol May 17; [Epub ahead of print]

67.

Voigt W, Behrmann C, Schlueter A et al. (2002) A new chemoembolization protocol in refractory liver metastasis of colorectal cancer – a feasibility study. Onkologie 25: 158–164PubMedCrossRef

68.

Wasser K, Giebel F, Fischbach R et al. (2005) Transarterial chemoembolization of liver metastases of colorectal carcinoma using degradable starch microspheres (spherex): personal investigations and review of the literature. Radiologe 45: 633–643PubMedCrossRef

69.

Vogl TJ, Zangos S, Balzer JO et al. (2002) Transarterial chemoembolization of liver metastases: Indication, technique, results. Rofo 174: 675–683PubMed

70.

Chan AO, Yuen MF, Hui CK et al. (2003) A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer 94: 1747–1752CrossRef

71.

Tarazov PG, Polysalov VN, Prozorovskij KV et al. (2000) Ischemic complications of transcatheter arterial chemoembolization in liver malignancies. Acta Radiol 41: 156–160PubMedCrossRef

72.

Song SY, Chung YW, Han JK et al. (2001) Liver abscess after transcatheter oily chemoembolization for hepatic tumors: incidence, predisposing factors, and clinical outcome. J Vasc Interv Radiol 12: 313–320PubMedCrossRef

73.

Wang MQ, Shao RH, Ye HY et al. (2005) Investigation of bile duct injury after transcatheter arterial chemoembolization. Zhonghua Zhong Liu Za Zhi 27: 609–612PubMed

Titel: Update Chemoperfusion und -embolisation
verfasst von: A. Lubienski
M. Simon
K. Lubienski
J. Gellissen
R.-T. Hoffmann
T.F. Jakobs
T. Helmberger
Publikationsdatum: 01.12.2007
Verlag: Springer-Verlag
Erschienen in: Die Radiologie / Ausgabe 12/2007
Print ISSN: 2731-7048
Elektronische ISSN: 2731-7056
DOI: https://doi.org/10.1007/s00117-007-1587-4

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Update Chemoperfusion und -embolisation

Zusammenfassung

Neu im Fachgebiet Radiologie

Darf man die Behandlung eines Neonazis ablehnen?

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Akuter Schwindel: Wann lohnt sich eine MRT?

Update Radiologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2007

Sturge-Weber-Syndrom

Primäre Degeneration des ZNS im Alter

Interventionelle Kombinationstherapien

Interventionelle Onkologie bei Lungentumoren

MRT des Kniegelenks

Interventionelle Onkologie in der Urologie

Neu im Fachgebiet Radiologie

Darf man die Behandlung eines Neonazis ablehnen?

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Akuter Schwindel: Wann lohnt sich eine MRT?

Update Radiologie